GW786034

DRUG5 trials

Sponsors

GlaxoSmithKline

Conditions

Carcinoma, Renal CellFallopian Tube CancerMacular DegenerationNeoplasms, OvarianOvarian CancerPeritoneal Cancer

Phase 1

Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

CompletedNCT00158782

GlaxoSmithKlineCarcinoma, Renal Cell

Start: 2004-09-28End: 2007-08-21Updated: 2017-11-17

A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans

CompletedNCT01051700

GlaxoSmithKlineMacular Degeneration

Start: 2010-01-12End: 2010-05-27Updated: 2017-11-14

Phase 2

GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma

CompletedNCT00244764

GlaxoSmithKlineCarcinoma, Renal Cell

Start: 2005-10-31End: 2013-09-30Updated: 2017-03-27

Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma

CompletedNCT00256880

GlaxoSmithKlineCarcinoma, Renal Cell

Start: 2005-01-31End: 2005-12-31Updated: 2017-01-18

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

CompletedNCT00281632

GlaxoSmithKlineFallopian Tube Cancer, Neoplasms, Ovarian, Ovarian Cancer +1

Start: 2006-03-31End: 2010-10-31Updated: 2018-09-17

Related Papers

Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?

2015-12-1522 citations

Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC).

Journal of Clinical Oncology2014-05-2010 citations

Initial Exploration of Oral Pazopanib in Healthy Participants and Patients With Age-Related Macular Degeneration

JAMA Ophthalmology2013-10-1128 citations